Telix Pharmaceuticals reports positive Phase 3 safety results for its investigational prostate cancer therapy, TLX591-Tx. The post Telix Pharmaceuticals reports positive TLX591-Tx Phase 3 results ...
FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...
The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper ...
Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.
Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...
An investigational approach to diagnosis of prostate cancer uses sound waves to extract "bubbles of information" from cells. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results